Treatments that suppress or alter immune system activity may help some children and adolescents with juvenile myasthenia gravis (JMG),…
Lila Levinson, PhD
Science Writer
Lila Levinson is a neuroscientist and science writer based out of Seattle. She joined Bionews in 2025 after completing her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Her research centered on developing techniques to measure brain connectivity using invasive neurotechnology in clinical populations. As a Wesleyan University undergraduate, she studied learning and memory in songbirds. She is passionate about telling science stories in accessible ways. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center.
Education
- PhD, Neuroscience, University of Washington (2024)
- BA, Neuroscience, Wesleyan University (2018)
Professional Organizations and Affiliations
- National Science Writers Association
- Northwest Science Writers Association
Published Works
- Levinson et al. (2024). “Data Processing Techniques Impact Quantification of Cortico-Cortical Evoked Potentials.” Journal of Neuroscience Methods.
- Levinson et al. (2020). “Intraoperative Characterization of Subthalamic Nucleus-to-Cortex Evoked Potentials in Parkinson’s Disease Deep Brain Stimulation.” Frontiers in Human Neuroscience.
Professional Accomplishments
- High Honors, Wesleyan University (2018)
- George H. Acheson and Grass Foundation Prize in Neuroscience, Wesleyan University (2018)
- Phi Beta Kappa, Wesleyan University Chapter (2017)
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lila Levinson, PhD
An eyedrop formulation of neostigmine, an acetylcholinesterase inhibitor (AChEI) whose oral formulation was once a mainstay treatment for myasthenia…
A single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis…
Nearly one year of treatment with Remegen’s telitacicept in a clinical trial in China led to substantial and sustained…
Vyvgart (efgartigamod) rapidly eased symptoms of generalized myasthenia gravis (gMG) and prevented complications before, during, and after surgery in…
People who begin experiencing symptoms of generalized myasthenia gravis (gMG) at the age of 65 or older tend to…
Nine-time tennis Grand Slam champion Monica Seles, who has myasthenia gravis (MG), is teaming up with pharmaceutical company…
Ultomiris (ravulizumab-cwvz) is now closer to being covered by public Canadian healthcare systems when used to treat adults with…
Treatment with Vyvgart (efgartigimod) eased hard-to-treat symptoms for a trio of women with generalized myasthenia gravis (gMG) who…
Women who have surgery to remove their thymus gland to treat myasthenia gravis (MG) tend to have experienced symptoms…